Martine Zimmermann
Direktor/Vorstandsmitglied bei INVENTIVA
Vermögen: 160 795 $ am 30.04.2024
Aktive Positionen von Martine Zimmermann
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INVENTIVA | Direktor/Vorstandsmitglied | 16.04.2021 | - |
| Independent Dir/Board Member | 16.04.2021 | - | |
| LIGAND PHARMACEUTICALS INCORPORATED | Direktor/Vorstandsmitglied | 26.09.2023 | - |
| Independent Dir/Board Member | 26.09.2023 | - | |
| Ipsen Biopharmaceuticals, Inc. | General Counsel | - | - |
Karriereverlauf von Martine Zimmermann
Ehemalige bekannte Positionen von Martine Zimmermann
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | General Counsel | 01.06.2016 | 01.02.2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | 01.03.2019 | 01.01.2021 |
Ausbildung von Martine Zimmermann
| University of Strasbourg | Doctorate Degree |
| Louis Pasteur University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Frankreich | 4 |
Operativ
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| General Counsel | 2 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| INVENTIVA | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Ipsen Biopharmaceuticals, Inc. | |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |
- Börse
- Insiders
- Martine Zimmermann
- Erfahrung
